Drug Development and Alzheimer's Disease

Pathy's Principles and Practice of Geriatric Medicine: Fifth Edition

Volumn 2, Issue , 2012, Pages 923-941

  Delrieu, Julien ^a   Piau, Antoine ^a   Vellas, Bruno ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Clinical trials; Disease modifying therapies

Indexed keywords

EID: 84886159595     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119952930.ch78     Document Type: Chapter

References (145)

1. Mori E, Hashimoto M, Krishnan KR and Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 2006;20(2 Suppl 1): S19-26.
2. Rees TM and Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today (Barc) 2003;39:75-83.
3. Ballard CG, Greig NH, Guillozet-Bongaarts AL et al. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005;2:307-18.
4. Mori E, Hashimoto M, Krishnan KR and Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 2006;20(2 Suppl 1): S19-26.
5. Zhang HY and Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006;27:619-25.
6. Li J, Wu HM, Zhou RL et al. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev 2008;(2): CD005592.
7. Wang R and Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 2005;14:71-82.
8. Greig NH, Sambamurti K, Yu QS et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005;2:281-90.
9. Kadir A, Andreasen N, Almkvist O et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008;63:621-31.
10. Lahiri DK, Chen D, Maloney B et al. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 2007;320:386-96.
11. Klein J. Phenserine. Expert Opin Investig Drugs 2007;16: 1087-97.
12. Lane RM, Potkin SG and Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9:101-24.
13. Kamal MA, Al-Jafari AA, Yu QS et al. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochim Biophys Acta 2006;1760:200-6.
14. Kamal MA, Klein P, Yu QS et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006;10:43-51.
15. Thal LJ, Forrest M, Loft H et al. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology 2000;54:421-6.
16. Messer WS Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 2002;19: 187-93.
17. Fisher A, Pittel Z, Haring R et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003;20:349-56.
18. Caccamo A, Oddo S, Billings LM et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006;49:671-82.
19. Arneric SP, Sullivan JP, Decker MW et al. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like and cytoprotective properties. Alzheimer Dis Assoc Disord 1995;9:50-61.
20. Lippiello PM, Bencherif M, Gray JA et al. RJR-2403: a nicotinic agonist withCNSselectivity II. In vivo characterization. J Pharmacol Exp Ther 1996;279:1422-9.
21. Bencherif M, Bane AJ, Miller CH et al. TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. Eur J Pharmacol 2000;409:45-55.
22. Lippiello P, Letchworth SR, Gatto GJ et al. Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci 2006;30:19-20.
23. Lin NH, Gunn DE, Ryther KB et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 1997;40:385-90.
24. Rueter LE, Anderson DJ, Briggs CA et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 2004;10:167-82.
25. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-81.
26. Dunbar GC, Inglis F, Kuchibhatla R et al. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007;21:171-8.
27. Jack CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
28. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
29. Morgan D, Diamond DM, Gottschall PE et al.Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5.
30. Lavie V, Becker M, Cohen-Kupiec R et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 2004;24:105-13.
31. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients withADafter ABeta42 immunization. Neurology 2003;61:46-54.
32. Hock C, Konietzko U, Streffer JR et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54.
33. Gilman S, Koller M, Black RS et al. Clinical effects of ABeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62.
34. Woodhouse A, Dickson TC and Vickers JC. Vaccination strategies for Alzheimer's disease: a new hope? Drugs Aging 2007;24:107-19.
35. Pride M, Seubert P, Grundman M et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008;5:194-6.
36. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9.
37. Goni F and Sigurdsson EM. New directions towards safer and effective vaccines for Alzheimer's disease. Curr Opin Mol Ther 2005;7:17-23.
38. Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36.
39. Rakover I, ArbelMand Solomon B. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 2007;4:392-402.
40. Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against betaamyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4.
41. Rinne JO, Brooks DJ, Rossor MN et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72.
42. Etcheberrigaray R, Tan M, Dewachter I et al. Therapeutic eff ects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A 2004;101:11141-6.
43. Marcade M, Bourdin J, Loiseau N et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008;106:392-404.
44. Hock C, Maddalena A, Raschig A et al. Treatment with the selective muscarinic M1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003;10:1-6.
45. Wienrich M, Meier D, EnsingerHAet al. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci 2001;68:2593-600.
46. Luo Y, Bolon B, Kahn S et al. Mice deficient in BACE1, the Alzheimer's betasecretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001;4:231-2.
47. Hussain I, Hawkins J, Harrison D et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 2007;100:802-9.
48. Watson GS and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003;17:27-45.
49. Watson GS, Cholerton BA, Reger MA et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-8.
50. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
51. Reger MA, Henderson ST, Hale C et al. Effects of betahydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;25:311-4.
52. ClinicalTrials.gov. http://www.clinicaltrials.gov (last accessed 8 July 2011).
53. Comery TA, Martone RL, Aschmies S et al. Acute gammasecretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2005;25:8898-902.
54. Dovey HF, John V, Anderson JP et al. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001;76:173-81.
55. Hartmann D, Tournoy J, Saftig P et al. Implication of APP secretases in notch signaling. JMol Neurosci 2001;17:171-81.
56. Barten DM, Meredith JE Jr, Zaczek R et al.Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 2006;7:87-97.
57. Wong GT, Manfra D, Poulet FM et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82.
58. Siemers E, Skinner M, Dean RA et al. Safety, tolerability and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-32.
59. Siemers ER, Dean RA, Friedrich S et al. Safety, tolerability and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30:317-25.
60. Siemers ER, Quinn JF, Kaye J et al. Effects of a gammasecretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-4.
61. Frick G., Raje S., Wan H. et al. P4-366: GSI-953, a potent and selective gammasecretase inhibitor: modulation of betaamyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/ pharmacodynamic relationships in humans. Alzheimer's Dementia 2008;4: T781.
62. Wilcock GK, Black SE, Hendrix SB et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93.
63. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs 2005;19:989-96.
64. Gervais F, Paquette J, Morissette C et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28:537-47.
65. Wright TM. Tramiprosate. Drugs Today (Barc) 2006;42: 291-8.
66. Finefrock AE, Bush AI and Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51:1143-8.
67. Cuajungco MP, Frederickson CJ and Bush AI. Amyloidbeta metal interaction and metal chelation. Subcell Biochem 2005;38:235-54.
68. Dedeoglu A, Cormier K, Payton S et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004;39:1641-9.
69. Lee JY, Friedman JE, Angel I et al. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004;25:1315-21.
70. Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-91.
71. Sampson E, Jenagaratnam L and McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2008;(1): CD005380.
72. Liu G, Garrett MR, Men P et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 2005;1741:246-52.
73. Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-86.
74. Phiel CJ, Wilson CA, Lee VM et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435-9.
75. Zhao WQ, Feng C and Alkon DL. Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. Neurobiol Dis 2003;14:458-69.
76. Wei Q, Holzer M, Brueckner MK et al. Dephosphorylation of tau protein by calcineurin triturated into neural living cells. Cell Mol Neurobiol 2002;22:13-24.
77. Hong M, Chen DC, Klein PS et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase- 3. J Biol Chem 1997;272:25326-32.
78. Rockenstein E, Torrance M, AdameAet al.Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007;27:1981-91.
79. Hampel H, Ewers M, Bürger K et al. Lithium trial in Alzheimer's disease: a randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study. Alzheimer's Dementia 2008;4: T782.
80. Deiana S, Harrington CR, Wischik CM et al. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009;202:53-65.
81. Nunomura A, Castellani RJ, Zhu X et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-41.
82. Keller JN, Schmitt FA, Scheff SWet al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152-6.
83. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67.
84. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
85. Miller ER III, Pastor-Barruiuso R, Dalal D et al. Meta analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
86. Isaac M, Quinn R and Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2000;(4): CD002854.
87. Lee DH, Folsom AR, Harnack L et al. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-200.
88. Barberger-Gateau P, Raffaitin C, Letenneur L et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007;69:1921-30.
89. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-8.
90. Holmquist L, Stuchbury G, Berbaum K et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113:154-64.
91. Moreira PI, Harris PL, Zhu X et al. Lipoic acid and N-acetylcysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 2007;12:195-206.
92. Hager K, Kenklies M, McAfoose J et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J Neural Transm Suppl 2007;72:189-93.
93. Ramassamy C, Longpré F and Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res 2007;4:253-62.
94. Tauskela JS. MitoQ - a mitochondria-targeted antioxidant. IDrugs 2007;10:399-412.
95. Wang S, Zhu L, Shi H et al. Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem Res 2007;32:1329-35.
96. Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
97. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
98. Tabet N and Feldman H. Indomethacin for Alzheimer's disease. Cochrane Database Syst Rev 2002;(2): CD003673.
99. De Jong D, Jansen R, Hoefnagels W et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE 2008;3: e1475.
100. Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
101. Soininen H, West C, Robbins J et al. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:8-21.
102. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289: 2819-26.
103. Geerts H. Drug evaluation: (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs 2007;10:121-33.
104. Brode S and Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008;28:109-26.
105. Tobinick EL and Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008;5: 2.
106. Harikumar KB and Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008;7:1020-35.
107. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901.
108. Greenamyre JT and Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989;10:593-602.
109. Chohan MO and Iqbal K. From tau to toxicity: emerging roles ofNMDAreceptor in Alzheimer's disease. JAlzheimers Dis 2006;10:81-7.
110. Zoladz PR, Campbell AM, Park CR et al. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav 2006;85:298-306.
111. Dicou E, Rangon CM, Guimiot F et al. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res 2003;970:221-5.
112. Quirk JC and Nisenbaum ES. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 2002;8:255-82.
113. Chappell AS, Gonzales C, Williams J et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-12.
114. Conner JM, Darracq MA, Roberts J et al. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci U S A 2001;98:1941-6.
115. Capsoni S, Giannotta S and Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 2002;99:12432-7.
116. Tuszynski MH, Thal L, Pay M et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-5.
117. Grundman M, Capparelli E, Kim HT et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci 2003;73:539-53.
118. Elder GA, De Gasperi R and Gama Sosa MA. Research update: neurogenesis in adult brain and neuropsychiatric disorders. Mt Sinai J Med 2006;73:931-40.
119. Lovell MA, Geiger H, Van Zant GE et al. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol Aging 2006;27:909-17.
120. Hogervorst E, Williams J, Budge M et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a metaanalysis. Neuroscience 2000;101:485-512.
121. Webber KM, Perry G, Smith MA et al. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007;5:177-83.
122. Casadesus G, Garrett MR, Webber KM et al. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. Drugs R D 2006;7:187-93.
123. Cherrier MM, Matsumoto AM, Amory JK et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005;64:2063-8.
124. Cherrier MM, Asthana S, Plymate S et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001;57:80-8.
125. Merriam GR, Schwartz RS and Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine 2003;22:41-8.
126. Sevigny JJ, Ryan JM, van Dyck CH et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008;71:1702-8.
127. Green KN, Billings LM, Roozendaal B et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 2006;26:9047-56.
128. Pomara N, Doraiswamy PM, Tun H and Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002;58: 1436.
129. Bachurin S, Bukatina E, Lermontova N et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001;939:425-35.
130. Doody RS, Gavrilova SI, SanoMet al. Effect of Dimebon on cognition, activities of daily living, behaviour and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15.
131. Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-7.
132. Simons M, Schwärzler F, Lütjohann D et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52: 346-50.
133. Jones RW, Kivipelto M, Feldman H et al. The Atorvastatin/ Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement 2008; 4:145-53.
134. Stuchbury G andMünch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 2005;112:429-53.
135. Maczurek A, Shanmugam K and Münch G. Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci 2008; 1126:147-51.
136. Schechter LE, Smith DL, Rosenzweig-Lipson S et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005;314:1274-89.
137. Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 2006;3:541-50.
138. Chan A and Shea TB. Folate deprivation increases presenilin expression, gammasecretase activity and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosylmethionine. J Neurochem 2007;102:753-60.
139. Cotelli M, Manenti R, Cappa SF et al. Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. Eur J Neurol 2008;15:1286-92.
140. Laxton AW, Tang-Wai DF, McAndrews MP http://www. ncbi.nlm.nih.gov/pubmed?term=%22Zumsteg%20D%22 %5BAuthor%5D et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521-34.
141. Brookmeyer R, Johnson E, Ziegler G et al. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91.
142. Andrieu S, Gillette S, Amouyal K et al. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003;58:372-7.
143. Vellas B, Andrieu S, Ousset PJ et al. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006;67(9 Suppl 3): S6-11.
144. Gillette-Guyonnet S, Andrieu S, Dantoine T et al. Commentary on 'A roadmap for the prevention of dementia II. Leon Thal Symposium 2008. The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease.' Alzheimers Dement 2009;5: 114-21.
145. Mangialasche F, Solomon A, Winblad B et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16.